Literature DB >> 16360387

Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring.

Jonathan C Hundley1, Derek T Woodrum, Brian D Saunders, Gerard M Doherty, Paul G Gauger.   

Abstract

BACKGROUND: Chronic lithium therapy may cause hyperparathyroidism (HPT). The utility of intraoperative parathyroid hormone monitoring (IOPTH) in these patients is unknown. The authors' hypothesis was that multiglandular disease is more common in these patients, and the ability of IOPTH to predict cure may be limited.
METHODS: Twelve patients had HPT during chronic lithium therapy and underwent parathyroidectomy with IOPTH. Criteria for curative resection were a decrease > or =50% from baseline and into the normal range. Calcium and PTH levels were measured during follow-up.
RESULTS: Preoperatively, mean calcium was 11.0 +/- 0.1 mg/dL, and PTH was 116 +/- 14 pg/mL. Fifty percent of patients had multiglandular disease confirmed by IOPTH levels. Mean IOPTH decrease from baseline was 74 +/- 4%. Although 10 of 12 patients met criteria for curative resection, only 8 remain normocalcemic. The 2 patients who did not meet criteria remain normocalcemic. Mean postoperative calcium for all patients was 9.5 +/- 0.2 mg/dL. Of the 10 normocalcemic patients, 4 also have hyperparathormonemia (mean PTH, 119 +/- 19 pg/mL).
CONCLUSIONS: The incidence of multiglandular disease in HPT after chronic lithium exposure is higher than standard HPT. The ability of IOPTH to predict durable normocalcemia is limited. Bilateral neck exploration should be considered for these patients regardless of whether IOPTH monitoring is used.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360387     DOI: 10.1016/j.surg.2005.09.028

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Identification of Acer2 as a First Susceptibility Gene for Lithium-Induced Nephrogenic Diabetes Insipidus in Mice.

Authors:  Theun de Groot; Lena K Ebert; Birgitte Mønster Christensen; Karolina Andralojc; Lydie Cheval; Alain Doucet; Cungui Mao; Ruben Baumgarten; Benjamin E Low; Roger Sandhoff; Michael V Wiles; Peter M T Deen; Ron Korstanje
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

2.  Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy.

Authors:  Anita R Skandarajah; F Fausto Palazzo; Jean-François Henry
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

3.  Intraoperative parathyroid hormone monitoring in patients with recognized multiglandular primary hyperparathyroidism.

Authors:  David T Hughes; Barbra S Miller; Gerard M Doherty; Paul G Gauger
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

4.  Every reason to discontinue lithium.

Authors:  Manuel E Fuentes Salgado; Bruce Sutor; Robert C Albright; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2014-11-08

Review 5.  Lithium nephrotoxicity revisited.

Authors:  Jean-Pierre Grünfeld; Bernard C Rossier
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

6.  Appropriate surgical treatment of lithium-associated hyperparathyroidism.

Authors:  Evie Carchman; Jennifer Ogilvie; Jennifer Holst; John Yim; Sally Carty
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 7.  Lithium therapy and hyperparathyroidism: an evidence-based assessment.

Authors:  Brian D Saunders; Erika F H Saunders; Paul G Gauger
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

8.  Hypercalcemia in patients with bipolar disorder treated with lithium: a cross-sectional study.

Authors:  Bas A Twigt; Bernard M Houweling; Menno R Vriens; Eline J Regeer; Ralph W Kupka; Inne Hm Borel Rinkes; Gerlof D Valk
Journal:  Int J Bipolar Disord       Date:  2013-09-16

9.  Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management.

Authors:  Adrian D Meehan; Ruzan Udumyan; Mathias Kardell; Mikael Landén; Johannes Järhult; Göran Wallin
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.